In agreement with this finding, Choi et al. [58] stated that pediatric kidney transplant recipients who were CYP3A5 expressers with high tacrolimus IPV showed poor clinical outcomes, while CYP3A5 genetic variants had no impact on tacrolimus IPV. The gene discussed is CYP3A5; the disease is kidney transplant.